Cargando…
Tall cell variant papillary thyroid carcinoma in Saudi patients: A clinicopathological and outcomes analysis
OBJECTIVES: To evaluate the clinicopathological features and treatment outcomes of papillary thyroid carcinoma tall cell variant (PTC-TCV) in Saudi population. METHODS: This retrospective study were medical records of 776 treated PTC patients between December 2007 and 2015, at King Fahad Medical Cit...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Saudi Medical Journal
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5303799/ https://www.ncbi.nlm.nih.gov/pubmed/27761560 http://dx.doi.org/10.15537/smj.2016.11.15480 |
_version_ | 1782506762138550272 |
---|---|
author | Al-Qahtani, Khalid H. Tunio, Mutahir A. Asiri, Mushabbab Al Bayoumi, Yasser Alshehri, Walaa A. Aljohani, Naji J. Ali, Ahmed Amir Fatani, Hanadi |
author_facet | Al-Qahtani, Khalid H. Tunio, Mutahir A. Asiri, Mushabbab Al Bayoumi, Yasser Alshehri, Walaa A. Aljohani, Naji J. Ali, Ahmed Amir Fatani, Hanadi |
author_sort | Al-Qahtani, Khalid H. |
collection | PubMed |
description | OBJECTIVES: To evaluate the clinicopathological features and treatment outcomes of papillary thyroid carcinoma tall cell variant (PTC-TCV) in Saudi population. METHODS: This retrospective study were medical records of 776 treated PTC patients between December 2007 and 2015, at King Fahad Medical City and King Khalid University Hospital, Riyadh, Kingdom of Saudi Arabia was probed for PTC-TCV. Total 42 (5.4%) patients were found to have PTC-TCV, which were investigated for demographic, symptoms, histopathological features, and treatment outcomes locoregional control (LRC), distant metastasis control (DMC), disease free survival (DFS), and overall survival (OS) rates. RESULTS: Mean age of cohort was 52.3 years (range: 46-80), with female predominance (73.8%). Mean tumor size was 3.62 cm (range: 0.4-10). Rates of LVSI (59.5%), positive pathological lymph nodes (66.7%), multifocality (42.9%) and extrathyroidal extension, (45.3%). Median follow-up was 37.4 months (range: 6-60). Local recurrence rate were seen in 6/42 (14.2%) patients and 8/42 (19%) developed distant metastasis. The 5 year rates of LRC (82.3%), DMC (77.8%), DFS (69.2%), and OS (86.7%) multivariate analysis showed PTC-TVC as an important independent prognosticator (odds ratio: 4.2; 95% confidence interval: 1.79-7.3; p=0.03) CONCLUSION: Papillary thyroid carcinoma tall cell variant is associated with aggressive biological behavior. |
format | Online Article Text |
id | pubmed-5303799 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Saudi Medical Journal |
record_format | MEDLINE/PubMed |
spelling | pubmed-53037992017-02-16 Tall cell variant papillary thyroid carcinoma in Saudi patients: A clinicopathological and outcomes analysis Al-Qahtani, Khalid H. Tunio, Mutahir A. Asiri, Mushabbab Al Bayoumi, Yasser Alshehri, Walaa A. Aljohani, Naji J. Ali, Ahmed Amir Fatani, Hanadi Saudi Med J Original Article OBJECTIVES: To evaluate the clinicopathological features and treatment outcomes of papillary thyroid carcinoma tall cell variant (PTC-TCV) in Saudi population. METHODS: This retrospective study were medical records of 776 treated PTC patients between December 2007 and 2015, at King Fahad Medical City and King Khalid University Hospital, Riyadh, Kingdom of Saudi Arabia was probed for PTC-TCV. Total 42 (5.4%) patients were found to have PTC-TCV, which were investigated for demographic, symptoms, histopathological features, and treatment outcomes locoregional control (LRC), distant metastasis control (DMC), disease free survival (DFS), and overall survival (OS) rates. RESULTS: Mean age of cohort was 52.3 years (range: 46-80), with female predominance (73.8%). Mean tumor size was 3.62 cm (range: 0.4-10). Rates of LVSI (59.5%), positive pathological lymph nodes (66.7%), multifocality (42.9%) and extrathyroidal extension, (45.3%). Median follow-up was 37.4 months (range: 6-60). Local recurrence rate were seen in 6/42 (14.2%) patients and 8/42 (19%) developed distant metastasis. The 5 year rates of LRC (82.3%), DMC (77.8%), DFS (69.2%), and OS (86.7%) multivariate analysis showed PTC-TVC as an important independent prognosticator (odds ratio: 4.2; 95% confidence interval: 1.79-7.3; p=0.03) CONCLUSION: Papillary thyroid carcinoma tall cell variant is associated with aggressive biological behavior. Saudi Medical Journal 2016-11 /pmc/articles/PMC5303799/ /pubmed/27761560 http://dx.doi.org/10.15537/smj.2016.11.15480 Text en Copyright: © Saudi Medical Journal http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Al-Qahtani, Khalid H. Tunio, Mutahir A. Asiri, Mushabbab Al Bayoumi, Yasser Alshehri, Walaa A. Aljohani, Naji J. Ali, Ahmed Amir Fatani, Hanadi Tall cell variant papillary thyroid carcinoma in Saudi patients: A clinicopathological and outcomes analysis |
title | Tall cell variant papillary thyroid carcinoma in Saudi patients: A clinicopathological and outcomes analysis |
title_full | Tall cell variant papillary thyroid carcinoma in Saudi patients: A clinicopathological and outcomes analysis |
title_fullStr | Tall cell variant papillary thyroid carcinoma in Saudi patients: A clinicopathological and outcomes analysis |
title_full_unstemmed | Tall cell variant papillary thyroid carcinoma in Saudi patients: A clinicopathological and outcomes analysis |
title_short | Tall cell variant papillary thyroid carcinoma in Saudi patients: A clinicopathological and outcomes analysis |
title_sort | tall cell variant papillary thyroid carcinoma in saudi patients: a clinicopathological and outcomes analysis |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5303799/ https://www.ncbi.nlm.nih.gov/pubmed/27761560 http://dx.doi.org/10.15537/smj.2016.11.15480 |
work_keys_str_mv | AT alqahtanikhalidh tallcellvariantpapillarythyroidcarcinomainsaudipatientsaclinicopathologicalandoutcomesanalysis AT tuniomutahira tallcellvariantpapillarythyroidcarcinomainsaudipatientsaclinicopathologicalandoutcomesanalysis AT asirimushabbabal tallcellvariantpapillarythyroidcarcinomainsaudipatientsaclinicopathologicalandoutcomesanalysis AT bayoumiyasser tallcellvariantpapillarythyroidcarcinomainsaudipatientsaclinicopathologicalandoutcomesanalysis AT alshehriwalaaa tallcellvariantpapillarythyroidcarcinomainsaudipatientsaclinicopathologicalandoutcomesanalysis AT aljohaninajij tallcellvariantpapillarythyroidcarcinomainsaudipatientsaclinicopathologicalandoutcomesanalysis AT aliahmedamir tallcellvariantpapillarythyroidcarcinomainsaudipatientsaclinicopathologicalandoutcomesanalysis AT fatanihanadi tallcellvariantpapillarythyroidcarcinomainsaudipatientsaclinicopathologicalandoutcomesanalysis |